Immunome, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMNM research report →
About the company
Immunome, Inc. , a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
- CEO
- Clay Siegall
- IPO
- 2020
- Employees
- 177
- HQ
- Bothell, WA, US
Price Chart
- Market Cap
- $2.26B
- P/E
- -9.88
- P/S
- 562.14
- P/B
- 4.54
- EV/EBITDA
- -7.57
- Div Yield
- 0.00%
- Gross Margin
- -1161.92%
- Op Margin
- -5947.90%
- Net Margin
- -5593.85%
- ROE
- -51.15%
- ROIC
- -40.31%
- Revenue
- $6.94M · -23.23%
- Net Income
- $-212,394,000 · 27.50%
- EPS
- $-2.43 · 51.40%
- Op Income
- $-214,113,000
- FCF YoY
- -22.09%
- 52W High
- $27.65
- 52W Low
- $7.96
- 50D MA
- $21.07
- 200D MA
- $19.83
- Beta
- 2.07
- Avg Volume
- 1.28M
Get TickerSpark's AI analysis on IMNM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 30, 26 | Barchas Isaac | sell | 101,050 |
| Jul 2, 26 | Barchas Isaac | sell | 75,665 |
| Jul 2, 26 | Barchas Isaac | sell | 24,335 |
| Jun 25, 26 | Lechleider Robert | other | 55,000 |
| Jun 25, 26 | Lechleider Robert | other | 55,000 |
| Jun 25, 26 | Lechleider Robert | sell | 40,580 |
| Jun 25, 26 | Lechleider Robert | sell | 14,420 |
| Jun 15, 26 | Rosett Max | other | 60,000 |
| Jun 15, 26 | Rosett Max | sell | 60,000 |
| Jun 15, 26 | Rosett Max | other | 60,000 |
Our IMNM coverage
Recent articles, reports, and earnings notes.
No research on IMNM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IMNM report →Similar companies
Peers in the same neighborhood.